Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension

Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman, Jean L. Chan, Mark Morris, Mason Yamashita, Alfred P. Spada, David Hagerty and Jaime Bosch

Yale University and VA-CT HCS New Haven, CT; McGuire DVAMC, Richmond, VA; Liver Institute of Virginia, Richmond, VA; Conatus Pharmaceuticals, San Diego, CA; Liver Unit, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.

The study was sponsored by Conatus Pharmaceuticals Inc.

Caspases play a central role in apoptosis and inflammation

Caspases produce hemodynamically-active, pro-inflammatory microparticles from apoptotic cells

In cirrhosis, these microparticles appear to contribute to the splanchnic and systemic vasodilatation that maintains and enhances portal hypertension Rautou PE et al. Gastroenterology 2012;143:166-176

Emricasan (IDN-6556), an oral pan-caspase inhibitor has been shown to
reduce portal pressure and improve survival in a murine model of portal
hypertensionhypertensionEguchi A, et al. Hepatology 2015 62(S1):1522 [AASLD abstract 953A]

To evaluate, in patients with compensated cirrhosis and portal hypertension, the effect of emricasan on:

- portal pressure (determined by the hepatic venous pressure gradient or HVPG)
- safety and tolerability

Emricasan lowers portal pressure and is safe in patients with compensated cirrhosis and portal hypertension

Prospective, proof-of-concept, multi-center (9 U.S. sites), open-label study

Emricasan administered orally at a dose of 25 mg twice a day for 28 days

Hepatic venous pressure gradient (HVPG) assessed before and after emricasan

One expert (J.B.) read all HVPG tracings


Investigators had access to all the data

Inclusion criteria

- Cirrhosis (HCV, NASH, limiting alcoholic etiology to <40%)
- Portal hypertension, i.e. HVPG > 5 mmHg

Main exclusion criteria

- Decompensation or HCC at entry
- Use of vasoactive drugs (beta-blockers, nitrates, PDE inhibitors)
- HCV-infected subjects receiving or planning on receiving anti-viral therapy during the course of the study
- Concomitant HIV infection
- Unwillingness to undergo contraception from screening to one month after last dose of emricasan



Methods: Study Outcomes

Primary (Baseline to Day 28)

- Change in HVPG
- Change in cCK18 serum levels (marker of apoptosis and indicator of caspase activity)

Secondary (Baseline to Day 28)

- Change in liver enzymes (ALT, AST), caspase 3/7, MELD, Child-Pugh score
- Development of decompensation

Safety Variables (Baseline to Day 56)

- Adverse events
- Vital signs
- Laboratory tests
- EKG (QTc interval)


- Analysis in the entire group
- Post-hoc analyses of baseline HVPG subgroups: <12 or ≥12 mmHg (severe portal hypertension)
 - Post-hoc sensitivity analysis conducted using an HVPG cutoff of 10 mmHg
- Analyses of primary endpoints used parametric tests given no major violations of normality
 - Sensitivity analyses using non-parametric tests yielded similar results

Results: Baseline Characteristics of the Cohort (N=23)

	Median*	Range (min, max)
Age (yrs)	59	48-80
Gender (% male)	16 (69.6%) male	N/A
Race (% Caucasian)	21 (91.3%) Caucasian	N/A
Etiology of cirrhosis		
- NASH	13 (56.5%)	N/A
- HCV (± alcohol)	9 (39.1%)	N/A
- Alcohol alone	1 (4.3%)	N/A
BMI (kg/m²)	32.4	17.9 – 44.9
Platelet count (K/mm ³)	104	43 - 199
ALT (U/L)	25	10 - 99
AST (U/L)	35	16 - 83
Total bilirubin (mg/dL)	0.73	0.31 – 3.08
Albumin (g/dL)	4.2	2.7 – 4.9
INR	1.1	0.9 – 1.6
Number with Child Class A	20 (87%)	N/A
MELD score	8	6 - 15
HVPG (mmHg)	13.5	5.5 – 32.0

*Except where percentages are in parentheses


Results: Overall, there were no significant differences in HVPG



*1 subject withdrew after 1 week due to adverse events of abdominal bloating and conjunctivitis (no follow-up HVPG)

Results:

A clinically meaningful reduction in HVPG was observed in patients with severe portal hypertension (HVPG ≥12 mmHg) at baseline




*p-value not adjusted for multiple testing

8/12 had a ≥10% decrease; 4/12 had a ≥20% decrease; 2/12 HVPG ↓ below 12 mmHg


Results:

Sensitivity analyses using HVPG cut-off of 10 mmHg (clinically significant portal hypertension) showed similar results



*p-value not adjusted for multiple testing

Results: cCK18 levels decreased in entire group but were relatively low at baseline



*p<0.05, not adjusted for multiple testing NS=not significant Data are geometric means

Results: Changes in clinical, biochemical and biomarker parameters

	HVPG < 12 mmHg (N=10)	р	HVPG ≥ 12 mmHg (N=13)	р
	Median (Range)		Median (Range)	
Systolic BP (mmHg)	-2 (-12, 16)	0.85	0 (-14, 17)	0.99
Heart rate (bpm)	-4 (-22, 10)	0.20	0 (-29, 24)	0.98
BMI (kg/m²)	+0.3 (-0.2, 1.5)	0.05	0 (-1.9, 1.4)	1.0
Platelet count (K/mm ³)	0 (-31, 24)	0.77	-8 (-33, 13)	0.08
AST (U/L)	-2.5 (-23, 68)	0.32	-4 (-29, 8)	0.03
ALT (U/L)	0 (-61, 43)	0.44	-5 (-15, 4)	0.008
Total bilirubin (mg/dL)	-0.1 (-0.6, 0.3)	0.29	0 (-0.4, 0.5)	0.78
Albumin (g/dL)	-0.15 (-0.4, 0.3)	0.16	-0.1 (-0.5, 0.4)	0.40
INR	0 (-0.1, 0.1)	0.34	0 (-0.2, 0.1)	0.74
MELD score	0 (-2, 1)	0.38	0 (-2, 2)	0.43
Caspase 3/7* (RLU)	-746 (-3452, 424)	0.009	-655 (-2337, 1107)	0.06

No correlation was found between changes in these parameters and changes in HVPG

Results: Emricasan was generally well tolerated

	Baseline HVPG			AEs occurring in	All subjects
	<12 mmHg ≥1	≥12 mmHg	All Subjects (N=23)	>5% subjects	N (%)
	(N=10)	(N=10) (N=13)		Fatigue	5 (21.7%)
Number of AEs	11	49	60*	Headache	3 (13.0%)
Number of related AEs	7	8	15	Peripheral	2 (42 00/)
Subjects with AEs	6 (60.0%)	9 (69.2%)	15 (65.2%)	edema	3 (13.0%)
Subjects with serious AEs	0	1 (7.7%)*	1 (4.3%)	Dehydration	2 (8.7%)
Subjects with moderate AEs	4 (40.0%)	6 (46.2%)	10 (45.3%)	Diarrhea	2 (8.7%)
Subjects with severe AEs	0	1 (7.7%)**	1 (4.3%)	Constipation	2 (8.7%)
Subjects with AEs leading to discontinuation	0	1 (7.7%)	1 (4.3%)	Nausea	2 (8.7%)

* One subject had 3 serious AEs (SIRS, acute respiratory failure, dyspnea) occurring 10 days after last dose of study drug, assessed unrelated, along with 24 other AEs

** All AEs except 2 (SIRS, anemia in the same subject with 3 SAEs) were mild to moderate in severity

• No clinically significant changes in routine labs, vital signs, or ECG (QTc)

No subject developed cirrhosis decompensation (ascites, encephalopathy, hemorrhage)

Study is small, not placebo-controlled, relatively short duration

Classification of patients with severe portal hypertension was established post-hoc

Emricasan administered orally for 28 days was associated with a clinically meaningful decrease in portal pressure in patients with compensated cirrhosis and severe portal hypertension

• Although a hemodynamic mechanism cannot be ruled out, concomitant decreases in AST/ALT suggest an intrahepatic effect

Emricasan was generally well-tolerated

Trials of longer duration will elucidate potential additional long-term effects due to microvascular remodeling or amelioration of vasodilatation

Randomized, placebo-controlled Phase 2 studies that will assess different doses of emricasan using an HVPG endpoint at 6 months are planned for 2016

Acknowledgements

Nine U.S. Sites Screened/Enrolled Subjects:

- Albert Einstein Medical Center (PI: Dr. Feyssa)
- Johns Hopkins Sibley Memorial Hospital (PI: Dr. Shetty)
- Liver Institute of Virginia 2 locations (PI: Dr. Shiffman)
- McGuire DVAMC (PI: Dr. Fuchs)
- Rutgers New Jersey Medical School (PI: Dr. Pyropoulos)
- University of Mississippi (PI: Dr. Borg)
- University of Pennsylvania (PI: Dr. Reddy)
- University of Utah (PI: Dr. Gallegos)
- Yale University, VA-CT HCS (PI: Dr. Garcia-Tsao)